Aitia
Aitia advances pharmaceutical R&D with their causal AI-based Gemini Digital Twin platform.
29 employees · est. 2010
Monte Rosa Therapeutics
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (M
221 employees · est. 2018 · Boston, United States
Aitia is the older company (2010 vs 2018); Monte Rosa Therapeutics is the larger of the two.
4 signals in the last 90 days
Side-by-Side Comparison
| Metric | Aitia | Monte Rosa Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2010 older | 2018 |
| Headquarters | ||
| Headquarters | Not tracked yet | Boston, United States |
| Employees | ||
| Employees | 29 | 221 larger |
| Industry | ||
| Industry | Not tracked yet | Biotechnology, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Series D | IPO |
| Total Funding | ||
| Total Funding | $33.00M | $570.50M |
| Funding Rounds | ||
| Funding Rounds | 2 | 9 |
| Services | ||
| Services | Gemini Digital Twins platform, causal AI reverse-engineering forward-simulation engine, development of in silico models, accelerating drug discovery and development | Discovery and development of molecular glue degraders (MGDs), Research on protein degradation for medical therapeutics, Innovation in AI and structural biology for drug discovery |
| Target Customers | ||
| Target Customers | biopharma partners, R&D teams, healthcare innovators, strategic pharma investors | Pharmaceutical companies, Healthcare providers, Medical researchers, Investors in biotechnology |
| Taxonomy | ||
| Taxonomy | Causal AI, Digital Twin, Pharmaceutical R&D, Supercomputing, Reverse-Engineering Forward-Simulation (REFS), Multiomics Data, Clinical Datasets, Drug Discovery, Biopharma Pipeline, Disease Biology Modeling, Targeted Drug Development, Oncology, Neurodegenerative Diseases, Immunological Diseases, Cardiometabolic Diseases | Clinical-stage, Molecular Glue Degraders, Oncology, Autoimmune Diseases, Inflammatory Diseases, QuEEN Discovery Engine, AI-guided Chemistry, Chemical Libraries, Structural Biology, Proteomics, Protein Degradation, Therapeutic Development, Selective Drug Design, Targeted Therapy |
| Website | ||
| Website | aitia.com | monterosatx.com |
About Aitia
Aitia is revolutionizing pharmaceutical R&D with its cutting-edge causal AI-based Gemini Digital Twin platform. Founded in 2010, the company integrates supercomputing capabilities with their proven causal AI reverse-engineering forward-simulation (REFS) engine to construct digital models of human di...
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, founded in 2018, is a United States-based clinical-stage biotechnology company at the forefront of developing highly selective molecular glue degrader (MGD) medicines. These innovations target patients with serious conditions across oncology, autoimmune, and inflammatory dis...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at Aitia and Monte Rosa Therapeutics — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at Aitia and Monte Rosa Therapeutic... — by email.
Frequently Asked Questions
Compare Aitia with someone else
Start typing a company name or domain.